NCT03990025

Brief Summary

This study aims to examine the use of Linked Color Imaging in detection of gastric cancer precursors, as well as oesophageal and duodenal lesions.

Trial Health

87
On Track

Trial Health Score

Automated assessment based on enrollment pace, timeline, and geographic reach

Enrollment
90

participants targeted

Target at P50-P75 for not_applicable

Timeline
Completed

Started Mar 2019

Geographic Reach
1 country

2 active sites

Status
completed

Health score is calculated from publicly available data and should be used for screening purposes only.

Trial Relationships

Click on a node to explore related trials.

Study Timeline

Key milestones and dates

First Submitted

Initial submission to the registry

March 27, 2019

Completed
Same day until next milestone

Study Start

First participant enrolled

March 27, 2019

Completed
3 months until next milestone

First Posted

Study publicly available on registry

June 18, 2019

Completed
1.3 years until next milestone

Primary Completion

Last participant's last visit for primary outcome

October 17, 2020

Completed
Same day until next milestone

Study Completion

Last participant's last visit for all outcomes

October 17, 2020

Completed
Last Updated

February 15, 2024

Status Verified

January 1, 2020

Enrollment Period

1.6 years

First QC Date

March 27, 2019

Last Update Submit

February 13, 2024

Conditions

Outcome Measures

Primary Outcomes (3)

  • Difference in detection rate of gastric lesions between Linked Color Imaging and White Light Imaging

    Includes Intestinal Metaplasia, Gastric Adenoma, Low Grade Dysplasia, High Grade Dysplasia, Early Gastric Cancer

    Immediately following the procedure

  • Difference in detection rate of oesophageal lesions between Linked Color Imaging and White Light Imaging

    Includes Barrett's Oesophagus, Low Grade Dysplasia, High Grade Dysplasia, Early Oesophageal Cancer

    Immediately following the procedure

  • Difference in detection rate of duodenal lesions between Linked Color Imaging and White Light Imaging

    Includes Duodenal adenoma, Duodenal adenocarcinoma

    Immediately following the procedure

Secondary Outcomes (3)

  • Sensitivity and Specificity of detection of gastric lesions

    Upon histological confirmation - within 2 weeks of the procedure

  • Sensitivity and Specificity of detection of oesophageal lesions

    Upon histological confirmation - within 2 weeks of the procedure

  • Sensitivity and Specificity of detection of duodenal lesions

    Upon histological confirmation - within 2 weeks of the procedure

Study Arms (2)

Linked Color Imaging - White Light Imaging

OTHER

Participant undergoes gastroscopy via Linked Color Imaging first, then followed by White Light Imaging

Diagnostic Test: Linked Color ImagingDiagnostic Test: White Light Imaging

White Light Imaging - Linked Color Imaging

OTHER

Participant undergoes gastroscopy via White Light Imaging first, then followed by Linked Color Imaging

Diagnostic Test: Linked Color ImagingDiagnostic Test: White Light Imaging

Interventions

Linked Color ImagingDIAGNOSTIC_TEST

Linked Color Imaging (LCI) is a form of image enhanced endoscopy that uses a laser endoscopic system that acquires images by simultaneously using narrow-band wavelength light and white light in an appropriate balance. This enhances slight color differences in the red region of the mucosa.

Linked Color Imaging - White Light ImagingWhite Light Imaging - Linked Color Imaging
White Light ImagingDIAGNOSTIC_TEST

White Light Imaging (WLI) uses conventional white light that encompasses all bandwidths of light to illuminate areas of interest to obtain endoscopic images.

Linked Color Imaging - White Light ImagingWhite Light Imaging - Linked Color Imaging

Eligibility Criteria

Age50 Years - 100 Years
Sexall
Healthy VolunteersNo
Age GroupsAdult (18-64), Older Adult (65+)

You may qualify if:

  • Patients aged 50 years and above
  • Patients undergoing gastroscopy for symptom evaluation
  • Patients undergoing gastroscopy for surveillance of known intestinal metaplasia

You may not qualify if:

  • Emergent gastroscopy performed for suspected acute GI bleeding
  • Patients with previous surgical/endoscopic resection in stomach
  • Patients with deranged coagulation and platelet function (INR\>1.5, Plt\<50)
  • Patients with severe comorbid illness (ASA 3 and above)

Contact the study team to confirm eligibility.

Sponsors & Collaborators

Study Sites (2)

Singapore General Hospital

Singapore, 169608, Singapore

Location

Changi General Hospital

Singapore, 529889, Singapore

Location

Related Publications (4)

  • Dohi O, Yagi N, Onozawa Y, Kimura-Tsuchiya R, Majima A, Kitaichi T, Horii Y, Suzuki K, Tomie A, Okayama T, Yoshida N, Kamada K, Katada K, Uchiyama K, Ishikawa T, Takagi T, Handa O, Konishi H, Naito Y, Itoh Y. Linked color imaging improves endoscopic diagnosis of active Helicobacter pylori infection. Endosc Int Open. 2016 Jul;4(7):E800-5. doi: 10.1055/s-0042-109049.

  • Paggi S, Mogavero G, Amato A, Rondonotti E, Andrealli A, Imperiali G, Lenoci N, Mandelli G, Terreni N, Conforti FS, Conte D, Spinzi G, Radaelli F. Linked color imaging reduces the miss rate of neoplastic lesions in the right colon: a randomized tandem colonoscopy study. Endoscopy. 2018 Apr;50(4):396-402. doi: 10.1055/a-0580-7405. Epub 2018 Mar 14.

  • Yao K. The endoscopic diagnosis of early gastric cancer. Ann Gastroenterol. 2013;26(1):11-22.

  • Sun X, Dong T, Bi Y, Min M, Shen W, Xu Y, Liu Y. Linked color imaging application for improving the endoscopic diagnosis accuracy: a pilot study. Sci Rep. 2016 Sep 19;6:33473. doi: 10.1038/srep33473.

MeSH Terms

Conditions

Stomach NeoplasmsBarrett Esophagus

Condition Hierarchy (Ancestors)

Gastrointestinal NeoplasmsDigestive System NeoplasmsNeoplasms by SiteNeoplasmsDigestive System DiseasesGastrointestinal DiseasesStomach DiseasesPrecancerous ConditionsEsophageal Diseases

Study Officials

  • Tiing Leong Ang, MBBS

    Changi General Hospital

    PRINCIPAL INVESTIGATOR

Study Design

Study Type
interventional
Phase
not applicable
Allocation
RANDOMIZED
Masking
TRIPLE
Who Masked
PARTICIPANT, CARE PROVIDER, OUTCOMES ASSESSOR
Purpose
DIAGNOSTIC
Intervention Model
CROSSOVER
Sponsor Type
OTHER
Responsible Party
SPONSOR

Study Record Dates

First Submitted

March 27, 2019

First Posted

June 18, 2019

Study Start

March 27, 2019

Primary Completion

October 17, 2020

Study Completion

October 17, 2020

Last Updated

February 15, 2024

Record last verified: 2020-01

Data Sharing

IPD Sharing
Will not share

Locations